

Liste der bewilligten Forschungsprojekte 2025 *Liste des projets de recherche acceptés en 2025*

Im [Forschungsportal](#) finden Sie Informationen zu allen Projekten, die die Stiftung Krebsforschung Schweiz und ihre Partnerorganisation Krebsliga Schweiz seit dem Jahr 2005 gefördert haben.

Dans le [portail de recherche](#), vous trouverez les informations sur tous les projets soutenus par la fondation Recherche suisse contre le cancer et son organisation partenaire, la Ligue suisse contre le cancer, depuis 2005.

Basic research

Bertoni Francesco | Resistance to BTK Inhibitors in B-cell lymphomas: ERBB4 signalling and therapeutic vulnerabilities

Faculty of Biomedical Sciences, USI, Institute of Oncology Research (IOR), Bellinzona
CHF 358 092 | 36 months | [KFS-6384-02-2025](#)

Hugues Stephanie | Cancer immunotherapy combinations based on novel A2AR negative allosteric modulators

Pathology and Immunology, Université de Genève (UNIGE), Geneva
CHF 368 607 | 36 months | [KFS-6358-02-2025-R](#)

Irving Melita | Gene-engineered TCR-T-cell therapies against sarcoma for clinical translation

Faculty of Biology and Medicine, Division Oncology, Ludwig Cancer Research, Epalinges
CHF 358 200 | 36 months | [KFS-6348-02-2025](#)

Joller Nicole | Impact of TIGIT-dependent tissue protection in cancer

Quantitative Biomedicine, Universität Zürich (UZH), Zürich
CHF 358 367 | 36 months | [KFS-6354-02-2025](#)

Läubli Heinz | Glyco-engineering cell therapies for the treatment of cancer

Medical Oncology, Department of Biomedicine, Universitätsspital Basel (USB), Basel
CHF 359 280 | 36 months | [KFS-6293-02-2025](#)

Meylan Etienne | Functional characterization of a mitochondria-enriched subset of neutrophils in non-small cell lung cancer

Faculté de Médecine et Faculté des Sciences, Université Libre de Bruxelles, Anderlecht
CHF 374 994 | 36 months | [KFS-6342-02-2025](#)

Moor Andreas | Targeting Plexin-B2 to prevent metastatic seeding

Department of Biosystems Science and Engineering (D-BSSE), Eidgenössische Technische Hochschule Zürich (ETHZ), Basel

CHF 375 000 | 36 months | [KFS-6368-02-2025](#)

Nageswara Rao Tata | Targeting the inflammatory-metabolic axis to ameliorate disease progression in myeloid neoplasms

Klinik for Oncology and Hematology, Kantonsspital St. Gallen (KSSG), St. Gallen

CHF 372 240 | 36 months | [KFS-6308-02-2025-R](#)

Oricchio Elisa | Decode how epigenetic heterogeneity contributes to lymphoma initiation and response to therapies

ISREC-SV, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne

CHF 370 200 | 48 months | [KFS-6319-02-2025](#)

Razansky Daniel | Nanoparticle-induced hyperthermia for targeted brain cancer therapy via focused ultrasound activation

Institute for Biomedical Engineering, Universität Zürich (UZH), Zurich

CHF 367 624 | 36 months | [KFS-6361-02-2025](#)

Roth Patrick | Advanced engineering and optimization of novel multifunctional SynNotch CAR T cells for the treatment of glioblastoma

Department of Neurology, Universitätsspital Zürich (USZ), Zürich

CHF 347 009 | 48 months | [KFS-6383-02-2025-R](#)

Schwaller Jürg | Functional characterization of a novel molecular dependency and potential therapeutic target of acute myeloid leukaemia (AML) driven by aberrant HOXA9/MEIS1 expression.

Departement Biomedizin DBM, Universitäts-Kinderspital beider Basel (UKBB), Basel

CHF 375 000 | 36 months | [KFS-6295-02-2025](#)

Stoffel Markus | Transforming the fibrotic stroma from limiting to enabling drug delivery for pancreatic cancer therapy

Molecular Health Sciences, Eidgenössische Technische Hochschule Zürich (ETHZ), Zürich

CHF 365 696 | 36 months | [KFS-6325-02-2025](#)

Clinical Research – laboratory-oriented

Alimonti Andrea | Exploring PMN-MDSC heterogeneity in prostate cancer

Institute of Oncology Research, Institute of Oncology Research (IOR), Bellinzona

CHF 370 500 | 36 months | [KFS-6323-02-2025](#)

Dawson Heather | ctDNA and attacker-defender model as clinical tools in locally advanced colon cancer: A prospective, interdisciplinary study
Institute of Tissue Medicine and Pathology, Universität Bern (UniBE), Bern
CHF 362 587 | 48 months | [KFS-6312-02-2025](#)

Galland Christophe | Label-free Surface Enhanced Raman Spectroscopy (SERS) for the follow-up, detection of response and recurrence in glioblastoma
Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne
CHF 327 196 | 48 months | [KFS-6391-02-2025-R](#)

Guerreiro Stücklin Ana S. | Longitudinal molecular and spatial analyses of recurrent paediatric low-grade gliomas
Department of Oncology and Children's Research Center, Universität Zürich (UZH), Zurich
CHF 341 743 | 36 months | [KFS-6375-02-2025](#)

Hottiger Michael O. | Investigating the anti-tumour activity of PARP7 inhibitors alone or in combination with drugs inducing nucleic acid signalling in NSCLC spheroids
Department of Molecular Mechanisms of Disease, Universität Zürich (UZH), Zürich
CHF 371 031 | 36 months | [KFS-6390-02-2025-R](#)

Rapsomaniki Marianna | AI-enabled precision oncology by multi-modal characterization of the tumour microenvironment in mesothelioma
Biomedical Data Science Center, Centre hospitalier universitaire vaudois (CHUV), Lausanne
CHF 362 272 | 48 months | [KFS-6340-02-2025-R](#)

Rossi Davide | Determinants of response to Bruton's Tyrosine Kinase inhibitors in marginal zone lymphomas
Lymphoma & Genomics Research Program, Institute of Oncology Research (IOR), Bellinzona
CHF 353 400 | 36 months | [KFS-6381-02-2025](#)

Clinical Research – patient-oriented

Bink Andrea | Amide proton transfer weighted and intra-voxel incoherent motion imaging in brain metastasis: a longitudinal study
Neuroradiology, Universitätsspital Zürich (USZ), Zürich
CHF 136 300 | 36 months | [KFS-6324-02-2025-R](#)

Britschgi Christian | A nutrition and exercise programme with olanzapine compared to olanzapine alone: a randomized controlled intervention trial in patients with advanced tumours
Med. Onkologie und Hämatologie, Kantonsspital Winterthur (KSW), Winterthur
CHF 334 740 | 42 months | [KFS-6338-02-2025-R](#)

Herrera Fernanda | A phase II non-randomized study of neoadjuvant induction chemotherapy and pembrolizumab followed by cisplatin chemo-radiation and pembrolizumab in locally-advanced cervical cancer

Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 375 000 | 36 months | [KFS-6311-02-2025-R](#)

Sandoval José Luis | No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial (NoELA)

Department of Oncology, Hôpitaux universitaires de Genève (HUG), Geneva

CHF 374 151 | 48 months | [KFS-6394-02-2025](#)

Stute Petra | Adherence to anti-estrogen therapy and correlation to blood steroidal biomarker in postmenopausal women with primary breast cancer Short title: STAY ON TRACK

Frauenheilkunde, Inselspital Bern, Bern

CHF 373 846 | 48 months | [KFS-6409-02-2025](#)

Turco Fabio | Intermittent androgen deprivation therapy in the era of androgen receptor pathway inhibitors: a phase 3 pragmatic randomized trial (DE-ESCALATE)

Oncology, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona

CHF 374 207 | 48 months | [KFS-6379-02-2025](#)

Epidemiological research

Ansari Marc | World-wide collaboration in childhood liver cancer research

Faculté de médecine, Département de pédiatrie, gynécologie et obstétrique, Université de Genève (UNIGE), Genève 14

CHF 57 500 | 24 months | [KFS-6288-02-2025](#)

Belle Fabiën | Trajectories of growth and weight of childhood cancer patients: from birth until late adulthood

Childhood Cancer Research Group, Universität Bern (UniBE), Bern

CHF 371 948 | 36 months | [KFS-6351-02-2025-R](#)

Kuehni Claudia E. | Exploring time trends and clusters of health behaviours among childhood cancer survivors in Switzerland

Institut für Sozial- und Präventivmedizin (ISPM), Universität Bern (UniBE), Bern

CHF 373 169 | 36 months | [KFS-6346-02-2025](#)

Mehra Tarun | Regional variation and determinants of treatment for early prostate cancer in Swiss cantons

Medizinische Onkologie und Hämatologie, Universitätsspital Zürich (USZ), Zürich

CHF 47 445 | 12 months | [KFS-6321-02-2025](#)

Health services research

Vokinger Kerstin Noëlle | Association between fast track approval and therapeutic value of cancer drugs— Improving expedited patient access to cancer drugs with high therapeutic value

Institute of Law, Universität Zürich (UZH), Zürich

CHF 93 957 | 11 months | [KFS-6386-02-2025](#)

Psychosocial research

Zwahlen Diana | Bridging the gap in psychosocial care for cancer survivors post-treatment: Integrating targeted digital screening with psychosocial care navigation call

Clinic for Psychosomatics, Universitätsspital Basel (USB), Basel

CHF 254 065 | 28 months | [KFS-6423-02-2025](#)

Fellowships

Köhler Paulina Valerie Charlotte | Deciphering dormancy in uveal melanoma: Unravelling tumor-intrinsic and microenvironmental pathways

Innere Medizin, Felix-Platter-Spital, Cambridge

CHF 64 000 | 24 months | [KFS-6363-02-2025 BIL](#)

Riggenbach Elena | Adaptive synergy in cervical cancer: integrating online adaptive external-beam radiotherapy with image-guided adaptive brachytherapy

Universitätsklinik für Radio-Onkologie, Inselspital Bern, Bern

CHF 55 000 | 12 months | [KFS-6362-02-2025 BIL](#)

Wyvekens Nicolas | Colibactin-induced mutagenesis in normal colorectal epithelial cells since the early 20th century. Insights into the global increase in early-onset colorectal cancer

Pathology and Molecular Pathology, Universitätsspital Zürich (USZ), Zürich

CHF 147 650 | 24 months | [KFS-6357-02-2025 BIL](#)